Complete Story


OPPA testifies on HB 378 related to opioid treatment limits

Prescription painkillers and heroin addiction is plaguing the state of Ohio, as well as the rest of the nation. However, limiting office-based treatment using buprenorphine products is not the solution.

The OPPA had an opportunity recently to share its concerns with Chairman Ryan Smith and members of the House Health & Aging Subcommittee on Opiate Addiction Treatment and Reform:

OPPA Testimony on HB 378 - Related to Office-Based Opioid Treatment Limits


Related Information:

OPPA opposes Medical Board draft rules on office-based opiate treatment using buprenorphine

Printer-Friendly Version